$186.15
-0.78%
2026-09-04 12:53:19 EDT-$1.47
헬스케어
의료 - 기기 및 소모품
NYSE
활발히 거래 중
전 세계적으로 운영되는 Becton, Dickinson and Company(BD)는 광범위한 의료 기술의 개발, 제조, 유통에 주력하는 대표적인 기업입니다. 여기에는 필수 의료 소모품, 정교한 장비, ...
T
Thomas E. Polen
Becton, Dickinson and Company
나이 53재임 기간 6y핵심 인물 리스크: Low
Tom Polen is a high-conviction, steady leader who has successfully transitioned BD from a legacy medical supply company into a modern medtech powerhouse. Investors benefit from his disciplined M&A strategy...
핵심 위험
•Economic volatility impacting hospital capital budgets
•Complex integration of a large global portfolio
•Increased competition in medical tech digital innovation
핵심 순풍
•Demographic trends increasing demand for medical devices
•Successful pivot to a higher-margin medtech focus
T
Thomas E. Polen
Becton, Dickinson and Company (BDX) · NYSE
American나이 53재임 기간 6 년비창업자 CEO핵심 인물 리스크: Low
Salisbury University (B.S.), Johns Hopkins University (MBA)
출신 배경
Tom Polen rose through the ranks at BD over two decades, gaining deep operational experience before ascending to the CEO role in 2020.
어린 시절: Polen joined BD in 1999 following the company's acquisition of an early-stage startup, demonstrating early adaptability and industry integration skills.
첫 기회: His tenure at BD began in 1999; his career gained significant momentum during a stint at Baxter Healthcare (2004–2009) where he led pharmaceutical business units before returning to BD.
CEO가 되기까지: Polen rejoined BD in 2009, subsequently leading multiple segments (Life Sciences, Medical). He played a key strategic role in the $24 billion acquisition of C.R. Bard in 2017, proving his capacity for large-scale integration before becoming CEO in 2020 and Board Chair in 2021.
초기 비전: To transform BD from a traditional medical supply company into a higher-growth, tech-enabled, and innovative global medtech leader.
Tom Polen has spent his entire career in the medical technology sector. After joining BD in 1999, he sharpened his executive skills at Baxter before returning to BD to lead various divisions. His ascent to the top was marked by his successful management of core business segments and his instrumental role in the transformative acquisition of C.R. Bard. Since becoming CEO in 2020, he has focused on steering the company through the complexities of the COVID-19 pandemic and implementing his 'BD 2025' growth strategy.
insiderstrategic leadermedtech veteran
투자 관점
Tom Polen is a high-conviction, steady leader who has successfully transitioned BD from a legacy medical supply company into a modern medtech powerhouse. Investors benefit from his disciplined M&A strategy...
긍정 요인
Demographic trends increasing demand for medical devices
Successful pivot to a higher-margin medtech focus
Effective R&D pipeline in smart, connected technologies
핵심 리스크
Economic volatility impacting hospital capital budgets
Complex integration of a large global portfolio
Increased competition in medical tech digital innovation
경력
A career dedicated to the medtech industry with a focus on operational growth and strategic acquisitions.
Becton, Dickinson and Company
이니셔티브: Chairman, CEO, and President
기간: 2009–Present
사건: Led successful 'BD 2025' strategy, managed COVID-19 response, completed 30+ acquisitions.
Baxter Healthcare
이니셔티브: Leadership roles in pharmaceuticals
기간: 2004–2009
사건: Led growth of pharmaceutical business units.
Becton, Dickinson and Company
이니셔티브: Various leadership roles
기간: 1999–2004
사건: Initial integration following company acquisition.
operational expertcareer insider
회사 성과
Performance is characterized by steady growth and significant portfolio transformation under his leadership.
매출: Revenue has shown consistent, low-single-digit to mid-single-digit growth, reaching ~$21-22 billion range by 2026.
수익성: Operating margins and EPS have been generally positive, supported by cost discipline and organic growth initiatives.
주가: The stock has performed in line with broader medtech peers, reflecting the stability of the core business and success of recent strategic pivots.
•Successful integration of C.R. Bard
•Effective navigation of global supply chain challenges post-COVID
•Expansion into high-growth medtech niches via tuck-in acquisitions
•Managing ongoing inflationary pressures and operational costs
•Integration complexity in a large, globalized portfolio
growth-orientedstable
경영 역량
Polen is viewed as a strategic, growth-minded operator who prioritizes innovation and cultural alignment.
스타일: Strategic operator
Polen emphasizes a 'growth mindset' across the organization. His management style relies on clear strategic pillars (Grow, Simplify, Empower), which have been critical in aligning a large, decentralized workforce of over 60,000 employees. He balances high-level M&A strategy with deep, operational focus on supply chain and digital innovation.
collaborativeprocess-driven
자본 배분
Strong focus on capital discipline and aggressive, value-adding M&A.
High discipline in integrating acquisitions to drive margins while maintaining a strong balance sheet.
C.R. Bard acquisition ($24B): Transformative, shifting BD into more lucrative medtech segments.
30+ tuck-in acquisitions: Broadened the portfolio and enhanced R&D capabilities.
Polen has utilized M&A as a primary engine for growth. His capital allocation approach is highly disciplined, favoring 'tuck-in' acquisitions that bolster existing segments rather than massive, overly dilutive bets. This balanced strategy supports margin improvement and consistent value creation.
serial acquirerdisciplined
자금 조달 및 파이낸싱
Maintains a conservative and healthy financing strategy with strong investor confidence.
Debt and credit facilities · Not specified: Successful financing of strategic M&A activities and portfolio development.
희석: minimal
The company maintains strong credit ratings and utilizes debt instruments effectively to fund its growth strategy without relying on excessive equity dilution. Investors view the current capital structure as robust, with sufficient liquidity to support ongoing R&D and future tuck-in deals.
conservative financingsolid credit
지배구조 및 통제
Governed by a standard public company board structure, ensuring robust shareholder oversight.
복수의결권 주식: 아니오
주식 클래스 상세: Single class common stock.
의결권 지배력: 0%
지분율: 0%
As CEO and Chairman, Polen maintains a strong influence on the board. The structure is traditional, ensuring board independence and alignment with long-term shareholders. There is no founder-control issue, as the company operates under standard governance protocols.
good governance
건강 및 승계
No public concerns; standard corporate succession processes are in place.
건강 상태: No public concerns.
승계 계획 공시: 예
핵심 인물 리스크: Low
Succession planning is handled by the Board of Directors, as standard for large-cap companies.
low risk
R&D 및 기술 비전
Innovation is a core priority, with substantial investments in digital and smart medical tech.
Sustained high-level investment in R&D, focusing on smart connected devices and diagnostics.
Smart connected devices: Ongoing, integral to the long-term roadmap.
High; effectively aligns with the digital health transformation in hospitals.
•Early focus on diagnostic efficiency post-COVID-19.
Polen prioritizes a culture of innovation, driving BD to move beyond simple manufacturing toward integrated digital healthcare solutions. The pipeline is robust, with a particular focus on smart devices that improve clinical workflow, safety, and patient outcomes.
tech-forwardinnovation-heavy
인재 채용
Maintains a strong corporate culture focused on development and performance.
Executive leadership team upgrades: Strengthened management across global functions.
Strong; composed of experienced industry veterans.
유지율: strong
Polen places a high premium on talent and 'associates.' He is known for driving a cohesive culture across 60,000+ employees and actively fostering diversity and inclusion as a business imperative. He has successfully recruited senior talent to lead key business units and digital initiatives.
culture-focusedtalent magnet
강점
Defined by his deep industry expertise, strategic foresight in M&A, and operational consistency.
Strategic Acumen: Led the highly successful integration of C.R. Bard and many other tuck-in acquisitions.
Operational Discipline: Consistent financial execution throughout the pandemic and global economic volatility.
disciplinedstrategic
약점 및 실패
Management of very large-scale global integrations remains a primary challenge.
Scale Complexity
Managing the integration and cost structure of an increasingly global and large product portfolio.
예시: Integration of diverse legacy units into a unified, lean system.
integration risk
마케팅 및 브랜드
Focuses on reinforcing BD's status as a leader in healthcare innovation.
Shifted perception toward a 'pure-play' medtech and digital health leader.
Marketing strategy centers on communicating the impact of BD's 38+ billion medical devices on clinical outcomes. Polen uses earnings calls and public forums to position the company as an essential, tech-forward partner in addressing complex global health challenges, such as chronic disease and diagnostic efficiency.
thought leadershipinnovation-focused
PR 및 커뮤니케이션
Communicates with transparency and professional authority, well-received by the investor community.
미디어 평판: positive
사건: COVID-19 pandemic
대응: Pivoted manufacturing rapidly; established BD as a reliable partner in diagnostics.
Polen is a frequent presence at investor conferences and public policy forums. His communication style is direct and focused on operational goals. He has successfully leveraged his calm, methodical approach to reassure stakeholders during periods of high volatility, such as the pandemic and inflationary cycles.
articulatemeasured
상류 / 하류 / 대체 기업